A NSW Government website


Haematology Research

The Concord Haematology Department delivers world-class tertiary Haematology clinical care, supported by active clinical, translational, and basic research. As one of the largest Haematology Clinical Research Units in NSW, we have recruited over 1000 patients to more than 140 trials since 2005.

Our Clinical Research Unit (CRU) is led by Dr Nicole Wong Doo (Director), Ms Jennfer Harman (Manager) and Ms Tafline Walker (Business Operations Manager). Our unit is staffed by a Clinical Coordination Division of 5 Registered Nurses and 5 Clinical Research Coordinators, all with tertiary science qualifications. Our highly skilled Business Operations Division efficiently meet our regulatory and reporting obligations, and support the team in various high-level administrative functions, in clinical trials governance and financial management. Ten haematologist investigators are supported by several clinical research fellows. 

Our broad portfolio with 28 currently recruiting trials and 32 trials in follow-up is particularly strong in trials in lymphoproliferative diseases. As a national leader in accessing emerging therapies, our unit has a high proportion of patients referred for clinical trial participation both within Sydney and across NSW and ACT. 

Our Key Research Themes and Achievements

Patient and Community Philanthropic Support

The Haematology Clinical Research Unit is supported by the Foundation for a Bloody Great Cause and their fundraising arm, the Bloody Great Committee. 2023 saw the introduction of our inaugural Bloody Great Fellow, Dr Monique Menzies-Wojtowicz, and the return of Patient Information Day, which saw over 100 patients and families attend talks by our haematologists, the Head of Infectious Diseases Associate Professor Tom Gottlieb, pharmacists, nurses and allied health professionals. Through the tremendous support of the local community, the Foundation/Committee raised over $200,000 in 2023, allowing the Unit the financial independence to support investigator-initiated and collaborative group trials and translational research. 

Planning is already underway for the signature Concord haematology clinical trials awareness and fundraising event, A Bloody Great Night Out! on Friday 18th October 2024. 

Our Research Team

Professor Judith Trotman Head of Department, Consultant Haematologist
Dr Nicole Wong Doo Haematology Clinical Research Unit Director, Consultant Haematologist
Associate Professor Vivien Chen Head Basic and Translational Research, Consultant Haematologist
Associate Professor Ilona Cunningham SLHD Clinical Director Cancer and Palliative Care, Consultant Haematologist
Dr Robin Gasiorowski Consultant Haematologist
Dr Emma Verner Consultant Haematologist 
Dr Janlyn Falconer Consultant Haematologist 
Dr Ibrahim Tohidi-Esfahani Consultant Haematologist 
Dr Marc Ellis Consultant Haematologist
Dr Praveen Gounder Locum, Consultant Haematologist
Dr Monique Menzies-Wojtowicz MBBS Clinical Trials Fellow
Dr Patrick Tunney Clinical Trials Fellow
Dr Ke Xu Clinical Trials Fellow
Jennifer Harman Clinical Nurse Specialist, Clinical Research Unit Manager
Adeline Kintono Clinical Trial Coordinator and Registered Nurse
Alexander Wong Clinical Trial Coordinator 
Andrea Salangsang Clinical Trial Coordinator and Registered Nurse
Lailamaryam Alkhouri Clinical Trial Coordinator 
Mili Patel Clinical Trial Coordinator 
Nathan Zhou Clinical Trial Coordinator 
Raquel Hermosilla Clinical Trial Coordinator 
Sarandar Kumar Clinical Trial Coordinator 
Sylvia Chan Clinical Trial Coordinator and Registered Nurse
Trieu Huynh Clinical Trial Coordinator and Registered Nurse
Tafline Walker Business Operations Manager
Alfredo Inton Administration Officer
Amanda Li Administration Officer
Georgia Klemm Administration Officer
Ekaterina Jebelev Administration Officer

Selected Grants

Amount awarded Grant and project details
$5,000,000 NHMRC Synergy Grant, 2020-2024
Addressing Australia’s National Transfusion Research Priorities
Investigators: Trotman J (CIG)
$2,900,000 MRFF, 2021-2024
A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector & m-RNA)
Investigators: Chen V, Tran, Passam, Phan, Wood, MacFadyen, Monagle
$2,752,967 MRFF, 2022-2026
Comparing Immunisation-boosting Regimens for COVID-19 Upon Initiation of immunosuppressive Therapies (CIRCUIT Study).
Investigators: Sasson S, Kelleher A, Petoumenos K, Davenport M, Trotman J, Brilot F, Turville S, Hamad N, Bull R, Ahlenstiel G
$2,490,422 NHMRC, 2021-2026
Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial
Investigators: Wood E (CIA), McQuilten Z (CIB), Morrissey CO (CIC), Trotman J (CID), Spencer A (CIE), Opat S (CIF), Fanning L (CIG), Reynolds J (CIH), Paterson D (CII), Mulligan S (CIJ)
$1,395,000 MRFF, 2021-2026
RADAR: A randomised PET-adapted study of bleomycin-free treatment of early-stage Hodgkin Lymphoma.
Investigators: Trotman J, Wong Doo N, Radford J, Berkahn L, Barrington S, Gandhi M, Opat S, Hawkes E, Cochrane T, Johnston A
$1,225,487 MRFF, 2021-2026
Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma.
Investigators: Hawkes E, Trotman J, Savage K, Keane C, Lee ST, Kuruvilla J, Cochrane T, Cheah CY, Gregory G, Johnston A
$1,000,000 NSW Cardiovascular Collaborative Grant, 2023-2025
Mechanisms of Vascular Thrombosis.
Investigators: Chen V, Passam F, Chong B, Pasalic L, Lee C, Leung H, Tohidi-Esfahani I
$659,293 MRFF, 2022-2024
Discovery of new platelet targets to improve the management of coronary artery disease.
Investigators: Passam F, Chen V, Weaver, Larance.
$193,000 NFMRI, 2022-2024
Novel Biomarker to predict thrombotic risk in myeloproliferative neoplasms.
Investigator: Chen V

Our Publications


Adattini JA, Gross AS, Doo NW, McLachlan AJ. Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia. Haematologica. 2023 Aug 1;108(8):2224-2228. doi: 10.3324/haematol.2022.282237.
Al-Mashhadi AL, Simonsen MR, Cheah CY, Amini RM, Arboe B, Cerhan JR, Chanchiri I, Clausen MR, Day J, Eyre TA, Ortved Gang A, Ghesquieres H, Habermann TM, Hawkes EA, Hwang SR, Jørgensen JB, Khurana A, Maquet C, Layshe N, Opat SS, El-Galaly TC. Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up. Blood. 2023 Nov 28; 142(1): 4396. https://doi.org/10.1182/blood-2023-173247 
Amaador K, Thieblemont C, Trotman J, Minnema MC. Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia. Hematol Oncol. 2023 Jul 17. doi: 10.1002/hon.3210. Epub ahead of print.
Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leuk Lymphoma. 2023 Mar;64(3):621-627. doi: 10.1080/10428194.2022.2157676. Epub 2022 Dec 21.
Baker RI, Gilmore G, Chen V, Young L, Merriman E, Curnow J, Joseph J, Tiao JY, Chih J, McRae S, Harper P, Tan CW, Brighton T, Royle G, Hugman A, Hankey GJ, Crowther H, Boey J, Gallus A, Campbell P, Tran H; Thrombosis and Haemostasis Society of Australia and New Zealand Anticoagulation Reversal and Events Study Collaborative. Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study. Res Pract Thromb Haemost. 2023 May 26;7(5):100196. doi: 10.1016/j.rpth.2023.100196.
Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Doo NW, Li EW, Gilbertson M, Shaw B, Bishton MJ, Saeed M, Ratnasingam S, Abeyakoon C, Chong G, Wai SH, Ku M, Lee HP, Fleming K, Tam C, Douglas G, Cheah CY, Ng ZY, Rolfe T, Mills AK, Hamad N, Cashman H, Gleeson M, Narayana M, Hawkes EA. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica. 2023 Sep 1;108(9):2444-2453. doi: 10.3324/haematol.2022.281375.
Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P, Phetsouphanh C, Warden A, Klemm V, Munier CML, Hoppe AC, Tea F, Pillay A, Stella AO, Aggarwal A, Lavee O, Caterson ID, Turville S, Kelleher AD, Brilot F, Trotman J. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. Am J Hematol. 2023 Jan;98(1):131-139. doi: 10.1002/ajh.26619. Epub 2022 Jun 9.
Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29.
Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia. Future Oncology. 2023 Feb; 19(5):345-353. https://doi.org/10.2217/fon-2022-1015 
Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Am J Hematol. 2023 Feb;98(2):338-347. doi: 10.1002/ajh.26788. Epub 2023 Jan 1. 
Cheah S, Bassett JK, Bruinsma FJ, Hopper J, Jayasekara H, Joshua D, MacInnis RJ, Prince HM, Southey MC, Vajdic CM, van Leeuwen MT, Wong Doo N, Harrison SJ, English DR, Giles GG, Milne RL. Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma. Expert Rev Hematol. 2023 Jul-Dec;16(10):773-783. doi: 10.1080/17474086.2023.2255747. Epub 2023 Sep 8.
Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Merriman E, Yong ASM, Simpson J, Gardiner E, Cherbuin N, Curnow J, Pepperell D, Bird R. Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. Res Pract Thromb Haemost. 2023 Jan;7(1):100009. doi: 10.1016/j.rpth.2022.100009. Epub 2022 Dec 13. 
Clarke L, Brighton T, Chunilal SD, Lee CSM, Passam F, Curnow J, Chen VM, Tran HA. Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. 2023 May 11;41(20):3285-3291. doi: 10.1016/j.vaccine.2023.03.071. Epub 2023 Apr 19.
Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M. SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study. Hemasphere. 2023 Jun 2;7(6):e887. doi: 10.1097/HS9.0000000000000887.
Dickinson M, Berkahn L, Trotman J, Butler J, Neeson P, Bressel M, Minson A. P1066: Pembrolizumab Monotherapy As A First Therapy For Hodgkin Lymphoma Is Deliverable In Older Or Abvd Ineligible Patients, Does Not Preclude Subsequent Therapy, And Provides Adequate Survival. HemaSphere. 2023 Aug;7(Suppl):e691267e. https://doi.org/10.1097/01.HS9.0000971160.69126.7e 
Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20;41(33):5099-5106. doi: 10.1200/JCO.22.02830. Epub 2023 Jul 21.
D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol. 2023 Mar;60(2):80-89. doi: 10.1053/j.seminhematol.2023.03.003. Epub 2023 Mar 27. 
Ellis ML, Alwis I, Smythe R, Yuan Y, Jackson SP. Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors. Blood Adv. 2023 Mar 28;7(6):982-986. doi: 10.1182/bloodadvances.2022008850.
Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5.
Fleming S, Reynolds J, Bajel A, Venn N, Kwan J, Moore J, Yeung D, Pati N, Leahy M, Kollipara S, Verner E, Berkakn L, Sutton R, Wei A, Greenwood M. P365: Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed ph-b-precursor acute lymphoblastic leukemia-final results of the ALLG ALL08 study. HemaSphere. 2023 Aug;7(Suppl). e811479d. https://doi.org/10.1097/01.HS9.0000968372.81147.9d 
Garcia-Manero G, Odenike O, Fleming S, Roboz GJ, Jacoby M, Cunningham I, Kreuzer  KA, Enjeti AK, Baer  MA, Cook R, Jurcic  J, Ku G, Zhou Y, Hoffman D, Potluri  J, Garcia JS. Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood. 2023 Nov 02; 142(1): 1868. https://doi.org/10.1182/blood-2023-187102 
Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv. 2023 Sep 12;7(17):5047-5054. doi: 10.1182/bloodadvances.2023010037.
Hawkes EA, Trotman J, Casulo C, Smith SM, LaCasce A; international Women in Lymphoma Steering Committee. Author gender representation of journal reviews and editorials on lymphoma (2017-22). Lancet. 2023 Aug 12;402(10401):523-525. doi: 10.1016/S0140-6736(23)01428-9. 
Johnson N, Lavie D, Borchmann P, Gregory G, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J. P1065: Updated results from an open-label phase 1/2 study of favezelimab in combination with pembrolizumab in patients with anti-pd-1-naive relapsed or refractory classical hodgkin lymphoma. HemaSphere. 2023 Aug;7(Suppl):e0274602. https://doi.org/10.1097/01.hs9.0000971156.02746.02 
Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J. A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies. Blood. 2023 Nov 28; 142(1): 1693. https://doi.org/10.1182/blood-2023-182128 
Josefsson EC, Ramström S, Thaler J, Lordkipanidzé M; COAGAPO study group. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH. J Thromb Haemost. 2023 Aug;21(8):2291-2299. doi: 10.1016/j.jtha.2023.05.001. Epub 2023 May 10.
Jurczak W, Ghesquieres H, Karimi Y, Cheah C, Clausen MR, Do YR, Lewis D, Gasiorowski R, Kim TM, Van Der Poel M, Poon ML, Feldman T, Linton K, Sureda A, Hutchings , Kanoun S, Vercellino L, Cota Stirner M, Mcgoldrick S, Liu Y, Sacchi M, Lugtenburg P, Thieblemont C. P1118: Longer follow-up from the pivotal epcore NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large b-cell lymphoma. HemaSphere. 2023 Aug;7(Suppl). e081065c. https://doi.org/10.1097/01.HS9.0000971368.08106.5c 
Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon MLM, Feldman TA, Linton KM, Sureda A, Hutchings M, Cota Stirner M, Sacchi M, Thieblemont C. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. Journal of Clinical Oncology. 2023 Jun 01; 41(16), 7525-7525. https://doi.org/10.1200/JCO.2023.41.16_suppl.7525 
Karimi Y, Ghesquieres H, Jurczak W, Cheah CY, Clausen MR, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Stirner MC, Liu Y, Kilavuz N, Thieblemont C. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma, Myeloma and Leukemia. 2023 Sep 1;23:S438. https://doi.org/10.1016/S2152-2650(23)01330-7
Kostakoglu L, Martelli M, Sehn LH, Davies A, Trněný M, Herold M, Vitolo U, Hiddemann W, Trotman J, Knapp A, Mattiello F, Nielsen TG, Sahin D, Sellam G, Ward C, Younes A. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. EJHaem. 2023 Oct 9;4(4):1042-1051. doi: 10.1002/jha2.796.
Lay AJ, Dupuy A, Hagimola L, Tieng J, Larance M, Zhang Y, Yang J, Kong Y, Chiu J, Gray E, Qin Z, Schmidt D, Maclean J, Hofma B, Ellis M, Kalev-Zylinska M, Argon Y, Jackson SP, Hogg P, Passam FH. Endoplasmic reticulum protein 5 attenuates platelet endoplasmic reticulum stress and secretion in a mouse model. Blood Adv. 2023 May 9;7(9):1650-1665. doi: 10.1182/bloodadvances.2022008457.
Lee CSM, Clarke LJ, Kershaw GW, Tohidi-Esfahani I, Brighton TA, Chunilal S, Favaloro EJ, Tran H, Chen VM. Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms. Res Pract Thromb Haemost. 2023 Mar 25;7(3):100128. doi: 10.1016/j.rpth.2023.100128.
Li EW, Krishnaswamy M, El-Wahsh S, Balgobind S, Trotman J, Tan I, Hardy TA. Paraneoplastic primary CNS angiitis secondary to nodular lymphocyte predominant Hodgkin lymphoma. Pathology. 2023 Jun;55(4):547-551. doi: 10.1016/j.pathol.2022.08.012. Epub 2022 Oct 29.
Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ, Wei AH. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood. 2023 Dec 7;142(23):1960-1971. doi: 10.1182/blood.2023020301. 
Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington SF, Radford J, Federico M, Kirkwood AA, Johnson PWM. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. J Clin Oncol. 2024 Jan 1;42(1):13-18. doi: 10.1200/JCO.23.01177. Epub 2023 Oct 26.
Mascuñano RC, Cheah CY, Tam CS, Lasica M, Verner E, Browett PJ, Anderson MA, Hilger J, Fang Y, Simpson D, Opat S. Phase 1 Study With the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor Sonrotoclax (BGB-11417) as Monotherapy or in Combination With Zanubrutinib for CLL/SLL: Preliminary Data. Sangre. 2023 Oct; 42(1): 268.
McKenzie CA, Gupta R, Jackett L, Anderson L, Chen V, Dahlstrom JE, Dray M, Farshid G, Hemmings C, Karim R, Kench JG, Klebe S, Kramer N, Kumarasinghe P, Maclean F, Morey A, Nguyen MA, O'Toole S, Rowbotham B, Salisbury ELC, Scolyer RA, Stewart K, Waring L, Cooper CL, Cooper WA. Looking beyond workforce parity: addressing gender inequity in pathology. Pathology. 2023 Oct;55(6):760-771. doi: 10.1016/j.pathol.2023.07.002. Epub 2023 Jul 25.
Mittal P, Quattrocchi G, Tohidi-Esfahani I, Sayar Z, Chandratheva A, Cohen H. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke. 2023 Apr;18(4):383-391. doi: 10.1177/17474930221150349. Epub 2023 Jan 25.
Nagaratnam S, Harinesan N, Wijesinghe R, Wong-Doo N, Lyons A, Morris K, Triplett J. Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis. J Neuroimmunol. 2023 Apr 15;377:578061. doi: 10.1016/j.jneuroim.2023.578061. Epub 2023 Mar 5.
Narayan SW, Gad F, Chong J, Chen VM, Patanwala AE. Preventability of venous thromboembolism in hospitalised patients. Intern Med J. 2023 Apr;53(4):577-583. doi: 10.1111/imj.15600. Epub 2022 Aug 13.
Nastoupil LJ, Song Y, Sehn LH, Sarkozy C, Zinzani PL, Salar A, Zhang J, Huang S, Wang J, Delarue R, Trotman J. MAHOGANY: A Phase 3 Trial of Zanubrutinib Plus Anti-CD20 Antibodies vs Lenalidomide Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal Zone Lymphoma. Journal of Clinical Oncology. 2023 May 31; 41(16). https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7590 
Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915. Epub 2022 Dec 28.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Erratum in: Ann Hematol. 2023 Sep;102(9):2643-2644. 
Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM. Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study. Front Nutr. 2023 Jan 4;9:1048301. doi: 10.3389/fnut.2022.1048301.
Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM. Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study. Occup Environ Med. 2023 Oct;80(10):599-602. doi: 10.1136/oemed-2023-108949. Epub 2023 Sep 18.
Opat S, Tedeschi A, Hu B, Linton K, Mckay P, Leitch S, Jin J, Sun M, Sobieraj-Teague M, Luigi Zinzani P, Browett P, Thieblemont C, Marina Liberati A, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Seok Kim J, Talaulikar D, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Long-Term Efficacy And Safety Of Zanubrutinib (Zanu) In Patients (Pts) With Relapsed/Refractory (R/R) Marginal Zone Lymphoma (Mzl): Final Analysis Of The Magnolia (Bgb-3111-214) Trial. Hemasphere. 2023 Aug 8; 7(Suppl ):e77003b0. https://doi.org/10.1097/01.HS9.0000971232.77003.b0 
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668.
Pennings GJ, Reddel CJ, Chen VM, Gnanenthiran SR, Kritharides L. Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Front Cardiovasc Med. 2023 Jan 19;9:1104744. doi: 10.3389/fcvm.2022.1104744. 
Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell. Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978. 
Phillips EH, Kirkwood AA, Hague C, Vestbo J, Federico M, D'Amore F, Fossa A, Trotman J, Berkahn L, Molin DL, Luminari S, Barrington SF, Johnson P, Radford J. Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial. Blood. 2023 Nov 28; 142(1): 612. https://doi.org/10.1182/blood-2023-185818 
Phillips K, Rijal S, Smyth L, Handunnetti S, Ngo C, Verner E, Trotman J, Agrawal S, Tatarczuch M, Tam C, Man SM. Impact of btki use in haematologic malignancies on inflammatory response signatures. International journal of laboratory hematology. International Journal of Laboratory Hematology. 2023 Jan 1; 4: 136-136. https://doi.org/10.1111/ijlh.14006 
Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clin Hematol Int. 2023 Mar;5(1):43-51. doi: 10.1007/s44228-022-00023-5. Epub 2023 Jan 19.
Rankin K, Hastak P, Wong A, Sasson SC, Beaton B, Yeola A, Warden A, Turville S, Kelleher AD, Brilot F, Trotman J. Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy. EJHaem. 2023 Jun 21;4(3):728-732. doi: 10.1002/jha2.724.
Reardon B, Smith S, Van Der Linde R, Sasson SC. Use of anti-JOVI. 1 antibodies to detect clonal T cell populations: implementation into a diagnostic flow cytometry laboratory and correlation with clinical findings. Pathology. 2023 Feb 1;55(1):S23. https://doi.org/10.1016/j.pathol.2022.12.077 
Ricard F, Barrington S, Korn R, Brueggenwerth G, Trotman J, Cheson B, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Schmid A. Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical). J Nucl Med. 2023 Feb;64(2):239-243. doi: 10.2967/jnumed.122.264124. Epub 2022 Jul 14.
Ricard F, Cheson B, Barrington S, Trotman J, Schmid A, Brueggenwerth G, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Korn R. Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical). J Nucl Med. 2023 Jan;64(1):102-108. doi: 10.2967/jnumed.122.264106. Epub 2022 Jul 14.
Rijal S, Lim JH, Smyth L, Coombes C, Jain S, Saxena K, Trotman J, Verner E, Gandhi MK, Gandhi K, Talaulikar D. Analysis of the genetic landscape in elderly diffuse large b cell lymphoma aged>= 75 years identifies new targetable mutations. International Journal of Laboratory Hematology. 2023 Jan 01; 45: 148-148. https://doi.org/10.1111/ijlh.14006 
Ross DM, Liang HPH, Iqra Z, Whittaker S, Tan CW, Dale BJ, Chen VM. Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin. Sci Rep. 2023 Jun 6;13(1):9172. doi: 10.1038/s41598-023-36266-2.
Santoro A, Johnson NA, Savage KJ, Avigdor A, Bazargan A, Borchmann P, Gasiorowski R, Gregory GP, Herishanu Y, Madan S, Minuk L, Musuraca G, Marceau West R, Pillai P, Marinello P, Zinzani PL. Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study. Blood. 2023 Nov 28; 142(1): 1725. https://doi.org/10.1182/blood-2023-182536 
Sehn L, Sarkozy C, Song Y, Salar A, Trotman J, Zinzani PL, Zhang J, Zhang W, Fustier P, Delarue R, Nastoupil L. MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma. Hematological Oncology. 2023 Jun; 41:168-170. https://doi.org/10.1002/hon.3163_T04 
Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Semin Thromb Hemost. 2023 Jul;49(5):444-452. doi: 10.1055/s-0043-1761269. Epub 2023 Jan 27.
Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, Wang ML, Kumar A, Trotman J, Alwan M, Ding W, By K, Tariq B, Chen X, Fabre S, Paik J, Agarwal A, Tam CS. First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101). Blood. 2023 Nov 28; 142(1): 4401. https://doi.org/10.1182/blood-2023-180109 
Silvestre AS, Trotman J, Sarkozy C, Song Y, Sehn LH, Nastoupil LJ, Zhang W, Fustier P, Delarue R, Zinzani. PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. HemaSphere. 2023 Aug;7(Suppl). e8253193. https://doi.org/10.1097/01.HS9.0000975836.58931.97 
Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson BM, Trotman J, Harrison SJ, Tam CS; Medical and Scientific Advisory Group, Myeloma Australia. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2023 Apr;53(4):599-609. doi: 10.1111/imj.15980. Epub 2023 Apr 5.
Tam C, Anderson MA, Lasica M, Verner E, Opat SS, Ma S, Weinkove R, Cordoba R, Soumerai J, Chia P, Leitch S, Hilger J, Fang Y, Simpson D, Guo H, Cheah CY. Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study. Blood. 2023 Nov 02; 142(1): 327. https://doi.org/10.1182/blood-2023-179541 
Tam C, Shadman M, Sharman J, Cull G, Phillips T, Trotman J, Cohen A, Allewelt H, Crescenzo R, Delarue R, Zhang H, Tariq B, Sahasranaman S, Ou YS, Flinn IW. PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES. HemaSphere. 2023 Aug;7(Suppl). e70124b5. https://doi.org/10.1097/01.HS9.0000974528.70124.b5 
Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990. 
Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S. A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2023 Feb;64(2):329-338. doi: 10.1080/10428194.2022.2150820. Epub 2022 Dec 8.
Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes EA, Ho SJ, Trotman J, Brasacchio D, Co M, Li J, Ramakrishnan V, Dunne K, Opat SS, Gregory GP. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood Adv. 2023 Jul 25;7(14):3531-3539. doi: 10.1182/bloodadvances.2022009412.
Tedeschi A, Cheah CY, Opat SS, Verner E, Magnano L, Epperla N, Hilger J, Fang Y, Simpson D, Guo H, Anderson MA. Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study. Blood. 2023 Nov 02; 142(1): 3032. https://doi.org/10.1182/blood-2023-178841 
Tedeschi A, Tam C, Owen R, Buske C, Leblond V, Dimopoulos MA, García-Sanz R, Castillo J, Trotman J, Treon S, Yang K, Tang B, Allewelt H, Patel S, Chan W, Cohen A, Schneider JY, Barnes Gisoo. P1679: Health-Related Quality Of Life In Patients (Pts) With Waldenström Macroglobulinemia (Wm) Treated With Zanubrutinib (Zanu) Vs Ibrutinib (Ibr): Results From The Phase 3 Aspen Trial Long-Term Follow-Up. HemaSphere. 2023 Aug 1; 7(S3):e27391ea. https://doi.org/10.1097/01.HS9.0000973588.27391.ea 
Terpos E, Branagan AR, García-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond V. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol. 2023 Mar;60(2):107-112. doi: 10.1053/j.seminhematol.2023.03.004. Epub 2023 Mar 29.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
Tobin JWD, Chowdhury R, Salvaris R, Griffin A, Chikatamarla V, Goh A, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Elizabeth S, Chen Y, Black H, Broadby G, Li L, Gutta N, Morris KL, Cochrane T, Hapgood G. The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival. Blood. 2023 Nov 28; 142(1): 1671. https://doi.org/10.1182/blood-2023-185879 
Tohidi-Esfahani I, Trotman J. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more. Br J Haematol. 2023 Jun;201(5):807-808. doi: 10.1111/bjh.18664. Epub 2023 Jan 30.
Tohidi-Esfahani I, Xing Y, Venturelli V, Gavriilaki E, Kang X, Isenberg D, Cohen H, Efthymiou M. Complement Activation Is Increased in Antiphospholipid Syndrome-Related Ischemic Stroke with Higher Risk Features. Blood. 2023 Nov 28; 142(2): 3943. https://doi.org/10.1182/blood-2023-182287 
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919.
Tran HA, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Gold M, Hissaria P, Melody S, Chunilal S SD, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E, Chen VM. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study. Lancet Reg Health West Pac. 2023 Sep 4;40:100894. doi: 10.1016/j.lanwpc.2023.100894.
Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C; Women in Lymphoma Steering Committee. Women in Lymphoma: A 4-year journey in promoting gender equity. Hematol Oncol. 2023 May 25. doi: 10.1002/hon.3183. Epub ahead of print.
Trotman J, Presgrave P, Carradice DP, Lenton DS, Gandhi MK, Cochrane T, Badoux X, Carlson J, Nkhoma G, Butcher B, Nikpour A, Fulham M, Johnston AM. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. Hemasphere. 2023 Feb 21;7(3):e836. doi: 10.1097/HS9.0000000000000836.
Trotman J, Zinzani PL, Mayer J, Flowers C, Bijou F, Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trneny M. P1080: Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the rosewood study. HemaSphere. 2023 Aug;7(Suppl). e2687131. https://doi.org/10.1097/01.HS9.0000971216.26871.31 
Trotman J, Zinzani PL, Mayer J, Flowers CR, Bijou F, de Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trněný M, Tilly H, Wojiech J, Ivanova E, Kim P, Greenbaum A, Huang S, Delarue R, Auer R. Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study. Hematological Oncology. 2023 Jun 9; 41(S2):119-121. https://doi.org/10.1002/hon.3163_81 
Trotman J, Zinzani PL, Song Y, Delarue R, Barnes G, Kim P, Ivanova E, Tang B, Mayer J, De Oliveira AC, Assouline S, Flowers CR. Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial. Blood. 2023 Nov 28; 142(1): 1674. https://doi.org/10.1182/blood-2023-181195 
van der Linde R, Smith S, Brown DA, Sasson SC, Tegg E. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method. Pathology. 2023 Apr;55(3):383-390. doi: 10.1016/j.pathol.2022.10.007. Epub 2022 Dec 30.
Verner E, Johnston A, Pati N, Hawkes E, Lee HP, Cochrane T, Cheah CY, Filshie R, Purtill D, Sia H, Enjeti AK, Brown C, Murphy N, Curnow J, Lee K, Gandhi M, Butcher B, Trotman J. P1127: Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: a phase ii study of ibrutinib, rituximab and mini-chop in very elderly patients with newly diagnosed BLBCL. HemaSphere. 2023 Aug;7(Suppl). e129974b https://doi.org/10.1097/01.hs9.0000971404.12997.4b 
Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, El-Galaly T, Cwynarski K, McKay P, Eyre TA. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. Am J Hematol. 2024 Feb;99(2):E46-E50. doi: 10.1002/ajh.27167. Epub 2023 Nov 30.
Wood EM, Chai KL, Reynolds J, Griffiths J, Beaton B, Callum J, Crassini KR, Crispin PJ, Fanning L, Gilbertson M, Grigg AP, Hawkes EA, Morrissey CO, Mulligan SP, Opat SS, Paterson DL, Petrie D, Roberts JA, Ryan EG, Spencer A,McQuilten ZK. Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain. Blood. 2023 Nov 28; 142(1): 1295. https://doi.org/10.1182/blood-2023-181541 
Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong A, Shortt J, Burbury K, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza AB, Wright M, Harrup RA, Forsyth C, Filshie R, Browett PJ, Lane S, Grove C. Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. Blood. 2023 Nov 02; 142(1): 865. https://doi.org/10.1182/blood-2023-172583
Yeung J, Dix CHK, Ritchie AG, Kow M, Chen VMY. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study. Intern Med J. 2023 Jan;53(1):68-73. doi: 10.1111/imj.15010. Epub 2022 Dec 5.
Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28.
Zlamal J, Aliotta A, Alberio L, Chen V, Bakchoul T; SSC Platelet Immunology of the ISTH. Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2024 Mar;22(3):860-868. doi: 10.1016/j.jtha.2023.11.019. Epub 2023 Dec 7.